Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. reported a net loss of $3.45 million for the quarter and $5.42 million for the six months ended June 30, 2025, driven by operating expenses including professional fees of $1.61 million and general and administrative costs of $1.11 million in the quarter. Research and development expense for the quarter was $514,814. Net loss per share was $(5.38) for the quarter and $(8.64) for six months on a weighted average share base of 626,736 for the six-month period.
Balance sheet and liquidity pressures are prominent: cash totaled $59,172 and the company reported a working capital deficit of about $6.5 million as of June 30, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Subsequent to the reporting period, the company completed a Merger and a PIPE financing that generated approximately $50.1 million in Series A Preferred Stock proceeds and effected a 10-for-1 reverse stock split and name change to Pelthos Therapeutics Inc., and also entered into royalty sale agreements related to ZELSUVMI and other products. These transactions materially change the company’s capital structure, ownership mix, and future revenue rights.
Pelthos Therapeutics (PTHS) filed a Form 4 for CEO, President and Director Scott M. Plesha covering equity awards dated 07/02/2025. The filing reports two grants: (1) 83,678 restricted stock units and (2) stock options for 255,000 common shares, both carrying a $13.50 exercise price.
Vesting schedule: one-third of each grant vests on 07/02/2026; the remaining two-thirds vest in equal quarterly installments over the following two years, fully vesting by mid-2028. All securities are held directly.
Following the awards, Plesha beneficially owns 83,678 RSUs and 255,000 options—together representing up to 338,678 additional common shares upon full vesting and exercise. The grants align executive incentives with shareholder value but, if exercised, would incrementally increase the company’s fully diluted share count.
PTHS Form 4 highlights: On 07/02/2025 Pelthos Therapeutics granted Chief Commercial Officer Sai Rangarao two equity awards.
- Restricted Stock Units: 30,518 RSUs at an exercise price of $13.50. One-third vests 07/02/2026; the balance vests quarterly over the following two years.
- Stock Options: 93,000 options, also at $13.50, with the same vesting schedule and a 07/02/2035 expiration.
No shares were sold; post-grant beneficial ownership equals the 30,518 RSUs and 93,000 options disclosed. The awards represent potential issuance of 123,518 common shares, introducing modest dilution but aligning the C-suite’s incentives with shareholder value creation. Investors may wish to track cumulative equity grants and future Form 4 filings to gauge insider sentiment and dilution trajectory.